** BofA Global Research starts coverage on insulin device maker Beta Bionics BBNX.O with "buy" rating and $25 PT, citing its "differentiated closed-loop algorithm" that simplifies insulin-dosing for diabetic patients
** PT represents a 21.4% upside to stock's last close
** Brokerage believes BBNX will help expand the current $2 billion U.S. insulin pump market, which has only seen 7% penetration growth in seven years
** Co's iLet insulin pump's simplicity can help those taking daily insulin injections switch to a simpler way - BofA
** Brokerage expects BBNX's revenue to grow by $15 mln in 2025 and $26 mln in 2026
** Stock has fallen 12.8% since its Nasdaq debut on 30 Jan
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.